Suki raises $90 million Series E funding to build AI agents for healthcare

Healthcare AI company Suki raised a $90 million Series E funding round led by Healthier Capital, Crosslink Capital, and Hercules Capital, bringing its total funding past $250 million. Suki will use the capital to build autonomous AI agents handling post-visit workflows such as referrals, prior authorizations, order filling, and scheduling. Amid competition from Epic, Oracle, Abridge, and Ambience Healthcare, Suki is expanding its tools across 30-plus tech partners including Optum, Zoom, and athenahealth.

Suki's funding history

• ▪Healthcare AI and ambient scribe company Suki raised a $90 million Series E funding round, led by new investors Healthier Capital, Crosslink Capital, and Hercules Capital alongside existing investors.
• ▪Suki has raised more than $250 million total across five funding rounds.

Development of post-visit AI agents

• ▪Suki plans to use its Series E funding to develop autonomous AI agents to manage post-visit healthcare tasks including referrals, prior authorizations for new medications, filling orders, and scheduling follow-ups.
• ▪Suki's planned AI agents will utilize clinical information gathered from the company's existing documentation and point-of-care tools to execute post-visit healthcare tasks.

Integrations with health technology partners

• ▪Suki currently powers athenahealth's Ambient Notes tool and the ambient documentation feature on the Zoom telehealth platform.
• ▪Suki plans to use its Series E funding to deepen integration with its more than 30 existing health technology partners, including Optum, Zoom, and athenahealth, by embedding new AI agent capabilities.

Competition in clinical AI market

• ▪Suki faces competition in the clinical AI documentation market from incumbent technology companies Epic and Oracle.
• ▪Competing AI clinical documentation startups Ambience Healthcare and Abridge raised $243 million and $300 million respectively in 2025 as they expanded beyond clinical notes.